Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | JUN | P05412 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3226180 | 1.00 | LMNA (0.56) | LMNAMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL2122980 | 0.79 | MMP2 (0.58) | LMNAMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL3226185 | 0.79 | LMNA (0.47) | LMNAMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL28450581 | 0.77 | LMNA (0.53) | LMNAMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL2184876 | 0.76 | KDM4E (0.67) | LMNAMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL2184878 | 0.76 | KDM4E (0.67) | LMNAMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL16585159 | 0.76 | KDM4E (0.67) | LMNAMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL17787987 | 0.75 | RAB9A (0.56) | LMNAMAPTRAB9AKDM4ENPC1 | |
| SCHEMBL27945376 | 0.74 | CYP1A2 (0.50) | LMNAMAPTRAB9ANPC1CYP1A2 | |
| SCHEMBL700810 | 0.74 | SMN1; SMN2 (0.58) | LMNAMAPTRAB9AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056499-A1 | 3-AMINO-1-ARYLPROPYL AZAINDOLES AND USES THEREOF | GREENHOUSE ROBERT | 2010-03-04 | — | — | US | disclosed |
| US-7638517-B2 | 3-Amino-1-arylpropyl azaindoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-12-29 | — | — | US | disclosed |
| EP-1957488-B1 | 3-AMINO-2-ARYLPROPYL AZAINDOLES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2009-09-09 | — | — | EP | disclosed |
| EP-1957488-A1 | 3-AMINO-2-ARYLPROPYL AZAINDOLES AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007062998-A1 | 3-AMINO-2-ARYLPROPYL AZAINDOLES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123535-A1 | 3-Amino-1-arylpropyl azaindoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123535-A1 | 3-Amino-1-arylpropyl azaindoles and uses thereof | CNKSR1, AR, CYP3A43 | LMNA 3077/4885MAPT 4436/4885RAB9A 690/4885 |
| US-20100056499-A1 | 3-AMINO-1-ARYLPROPYL AZAINDOLES AND USES THEREOF | CNKSR1, AR, CYP3A43 | LMNA 3077/4885MAPT 4436/4885RAB9A 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.